Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.69 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.69 |
| ▸ | GRAMD1A | Q96CP6 | 6/20 | 0.55 |
| ▸ | STAT3 | P40763 | 5/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23540331 | 0.95 | CRBN (0.67) | CRBNDDB1GRAMD1ASTAT3CA2 | |
| SCHEMBL22836586 | 0.94 | CRBN (0.69) | CRBNDDB1GRAMD1ASTAT3CA2 | |
| SCHEMBL22835837 | 0.93 | CRBN (0.68) | CRBNDDB1GRAMD1ASTAT3CA2 | |
| SCHEMBL21998063 | 0.92 | DDB1 (0.66) | CRBNDDB1GRAMD1ASTAT3 | |
| SCHEMBL21997070 | 0.91 | CRBN (0.72) | CRBNDDB1GRAMD1ASTAT3CA2 | |
| SCHEMBL23539331 | 0.91 | CRBN (0.72) | CRBNDDB1GRAMD1ASTAT3CA2 | |
| SCHEMBL32667999 | 0.91 | CRBN (0.72) | CRBNDDB1GRAMD1ASTAT3CA2 | |
| SCHEMBL30678698 | 0.87 | CRBN (0.58) | CRBNDDB1STAT3CA2 | |
| SCHEMBL21997087 | 0.87 | DDB1 (0.65) | CRBNDDB1GRAMD1ASTAT3 | |
| SCHEMBL29502409 | 0.87 | DDB1 (0.65) | CRBNDDB1GRAMD1ASTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12539295-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12150995-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240383887-A1 | DEUTERATED IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-11-21 | — | — | US | disclosed |
| US-20240316004-A1 | METHODS OF TREATING MUTANT LYMPHOMAS | KYMERA THERAPEUTICS, INC. | 2024-09-26 | — | — | US | disclosed |
| US-20240131016-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| EP-4333836-A1 | DEUTERATED IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230101353-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2022236339-A1 | DEUTERATED IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-4076520-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| EP-3989966-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20220054453-A1 | METHODS OF TREATING MUTANT LYMPHOMAS | KYMERA THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| WO-2022027058-A1 | METHODS OF TREATING MUTANT LYMPHOMAS | KYMERA THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
| WO-2021127190-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | CRBN 39/4885DDB1 511/4885GRAMD1A 4661/4885 |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885GRAMD1A 2556/4885 |
| US-12539295-B2 | IRAK degraders and uses thereof | IRAK2, IRAK4, IRAK3 | CRBN 70/4885DDB1 2951/4885GRAMD1A 4704/4885 |
| US-20220054453-A1 | METHODS OF TREATING MUTANT LYMPHOMAS | IRAK4, IRAK2, IRAK3 | CRBN 111/4885DDB1 291/4885GRAMD1A 2862/4885 |
| US-20240383887-A1 | DEUTERATED IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK1, IRAK3 | CRBN 203/4885DDB1 384/4885GRAMD1A 1311/4885 |
| US-20240131016-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885GRAMD1A 2556/4885 |
| US-12150995-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885GRAMD1A 2556/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | CRBN 79/4885DDB1 2480/4885GRAMD1A 4445/4885 |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885GRAMD1A 2556/4885 |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885GRAMD1A 2556/4885 |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK4, IRAK2, IRAK3 | CRBN 322/4885DDB1 68/4885GRAMD1A 2650/4885 |
| US-20240316004-A1 | METHODS OF TREATING MUTANT LYMPHOMAS | IRAK4, IRAK2, IRAK3 | CRBN 111/4885DDB1 291/4885GRAMD1A 2862/4885 |
| US-20230101353-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885GRAMD1A 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.